MS Multiple sclerosis
Conditions
Interventions
1000-mg intravenous infusions of rituximab on study days 1 and 15. Only the
first administration will be partially labelled with the positron emitter
Zirconium-89. PET scans will be performed on day
Sponsors
Vrije Universiteit Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Diagnosis of MS EDSS score 0.0 to 5.0 Age between 18 and 50 years >=1 MS attack(s) in the year prior to screening >=1 MS attack during treatment with interferon beta or glatiramer acetate
Exclusion criteria
Exclusion criteria: Previous treatment with mitoxantrone, natalizumab or any investigational drug for MS the year before screening Any progressive form of MS Inability to undergo MRI with gadolinium administration Pregnancy or breast feeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 89Zr-rituximab uptake in CD20 positive (actieve) MS lesions | — |
Secondary
| Measure | Time frame |
|---|---|
| Inter-patient variability in 89Zr-rituximab biodistribition. | — |
Countries
Netherlands
Outcome results
None listed